RxDoctor Payments Data

Jennifer Norman, MD

Neurology with Special Qualifications in Child Neurology · Oklahoma City, OKNPI 1437325438

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (53.8%), food and beverage and education — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by Novartis Gene Therapies, Inc. (fka Avexis, Inc.) at 54.3% of the total. Reporting peaked in 2020 at $5,796 and has fallen 87.1% since, to $746 in 2025.

$13,003in general payments, 2019–2025

Across 340 payments — averaging $38.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$7K
  • UCB, Inc.$2K
  • Neurelis, Inc.$492
  • Eisai Inc.$481
  • Livanova USA, Inc.$462
  • Immedica Pharma US, Inc.$334
  • plus $3K from 31 others

What the payments were for

  • Speaking & faculty fees$7,00054%
  • Food & beverage$5,94746%
  • Education$570%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few neurology with special qualifications in child neurology providers in Oklahomato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$4,766
Medicare patients
65
Services billed
72

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZonegranZonisamide12$30,733
AptiomEslicarbazepine Acetate12$14,784
Lacosamide12$4,092
Fluoxetine Hcl13$199
Clonazepam15$196
Sertraline Hcl12$84
Baclofen15$66
Paroxetine Hcl12$45
Amitriptyline Hcl11$9

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sunovion Pharmaceuticals Inc.Aptiom$296$14,78412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neurology with special qualifications in child neurology providers in Oklahomaon file to place this against a meaningful peer group, so we don't.

Other neurology with special qualifications in child neurology in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →